Business Context and Reporting Period
Company: GRI Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 21, 2024
Reporting Period: The filing covers events occurring on October 21, 2024, with the transaction closing on October 22, 2024.
The Company entered into Repricing Letter Agreements with holders of its Series B-1 and Series B-2 Warrants to reprice existing warrants and issue new warrants in exchange for cash proceeds.
Key Financial Metrics
- Gross Proceeds: $762,236 from the exercise of Prior Warrants.
- Shares Issued (Prior Warrants): 762,236 shares of Common Stock.
- Exercise Price (Prior Warrants): Reduced to $1.00 per share.
- Placement Agent Fees: 7.0% cash fee plus 1.0% management fee of gross proceeds.
- Expenses: $25,000 accountable expenses and $10,000 non-accountable expenses reimbursed to the placement agent.
- Placement Agent Warrants: 53,357 warrants issued to H.C. Wainwright & Co., LLC with an exercise price of $1.25 per share.
- Use of Proceeds: Working capital and general corporate purposes.
Note: This filing does not provide data on revenue, net income, operating cash flow, margins, or total debt levels.
Material Changes
The primary material change is the restructuring of warrant obligations and the immediate infusion of capital:
- Warrant Repricing: Holders of 762,236 Prior Warrants exercised them at a reduced price of $1.00 per share.
- New Warrant Issuance: In exchange, holders received new unregistered Series D-1 Warrants (5-year term) and Series D-2 Warrants (18-month term), each exercisable for up to 762,236 shares at $1.00 per share.
- Capital Raise: The Company secured $762,236 in gross proceeds, which will be net of placement agent fees and expenses.
Guidance, Outlook, and Risks
- Management Commentary: The Company intends to use net proceeds for working capital and general corporate purposes.
- Registration Obligations: The Company agreed to file a Resale Registration Statement within 30 calendar days and use commercially reasonable efforts to have it declared effective within 60 days (or 90 days in case of a full review).
- Lock-Up Provisions: The Company agreed not to issue or announce the issuance of Common Stock or equivalents for 5 calendar days after closing. It also agreed not to effect any Variable Rate Transaction for 1 year after closing.
- Risks/Contingencies: The New Warrants and Placement Agent Warrants were sold without registration under the Securities Act of 1933, relying on Section 4(a)(2) and Rule 506 exemptions. These securities cannot be resold in the U.S. absent registration or an exemption.
Investor Verification Checklist
- Verify the effective date of the Resale Registration Statement for the New Warrant Shares.
- Confirm the net proceeds after deducting the 8.0% total placement agent fees and $35,000 in reimbursable expenses.
- Review the dilution impact of the 1,524,472 New Warrant Shares (Series D-1 and D-2) plus 53,357 Placement Agent Warrants.
- Check for any subsequent filings regarding the "Variable Rate Transaction" restriction expiring one year post-closing.